(Albany, United States) As per DelveInsight’s assessment, globally, the PD-1 Non-Small Cell Lung Cancer Pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the PD-1 Non-Small Cell Lung Cancer Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PD-1 Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, PD-1 Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the PD-1 Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook

 

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report

• DelveInsight’s PD-1 Non-Small Cell Lung Cancer Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.
• The leading companies in the PD-1 Non-Small Cell Lung Cancer market include Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo Inc., Arcus Biosciences Inc., IO Biotech, Cellular Biomedicine Group Inc., and others.
• Promising PD-1 Non- Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Gotistobart, Docetaxel, REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, AZD9150, AZD6738, and others.
• On July 2023, OncoC4 Inc. announced a study of phase 3 clinical trials for Gotistobart and Docetaxel. The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients.
• On August 2023, Regeneron Pharmaceuticals announced a study of phase 3 clinical trials for REGN2810 and Chemotherapy. To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in <50% of tumor cells.

 

PD-1 Non-Small Cell Lung Cancer Overview

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

 

For further information, refer to the detailed PD-1 Non-Small Cell Lung Cancer Unmet Needs, click here for PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile

• Tislelizumab (BGB-A317) – BeiGene
• Canakinumab: Novartis Pharmarmaceutical
• PLB-1004: Avistone Biotechnology

 

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for PD-1 Non-Small Cell Lung Cancer. The companies which have their PD-1 Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Novartis Pharmaceutical.

 

Request a sample and discover the recent advances in PD-1 Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ PD-1 Non-Small Cell Lung Cancer Segmentation

 

PD-1 Non-Small Cell Lung Cancer Drugs and Companies

• Gotistobart: OncoC4 Inc.
• Docetaxel: BioNTech SE
• REGN2810: Regeneron Pharmaceuticals
• Chemotherapy: Sanofi

 

PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include-

Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo Inc., Arcus Biosciences Inc., IO Biotech, Cellular Biomedicine Group Inc., and others.

 

Dive deep into rich insights for drugs for PD-1 Non-Small Cell Lung Cancer Pipeline, click here @ PD-1 Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Companies- Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo Inc., Arcus Biosciences Inc., IO Biotech, Cellular Biomedicine Group Inc., and others.
• Therapies- Gotistobart, Docetaxel, REGN2810, Chemotherapy, CV301, Pembrolizumab, Nivolumab, Cyclophosphamide, AZD9150, AZD6738, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on PD-1 Non-Small Cell Lung Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. PD-1 Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. PD-1 Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Canakinumab: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MK-5890: Merck Sharp & Dohme
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BBP-398: Navire Pharma Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. PD-1 Non-Small Cell Lung Cancer Key Companies
21. PD-1 Non-Small Cell Lung Cancer Key Products
22. PD-1 Non-Small Cell Lung Cancer- Unmet Needs
23. PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. PD-1 Non-Small Cell Lung Cancer Analyst Views
26. PD-1 Non-Small Cell Lung Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services